The US Food and Drug Administration (FDA) has withdrawn orphan drug designation from a potential covid-19 treatment, after criticism that treating covid-19 as a rare disease was “disingenuous.” Pharmaceutical company Gilead requested that the FDA withdraw the designation—which was set to give the company a longer exclusivity period (seven years instead of five) and significant tax incentives—just days after it was given.1 Remdesivir, which works to inhibit viral replication, is a drug currently being investigated as a potential treatment for covid-19 through several …

中文翻译：

---

Covid-19：批评后，吉利德（Gilead）从潜在治疗中撤回了孤儿药的称号

在批评将covid-19视为罕见疾病后，美国食品和药物管理局（FDA）已从潜在的covid-19治疗中撤回了孤儿药的称号。制药公司吉利德（Gilead）要求FDA在指定后几天就撤回该名称，这是为了给予该公司更长的独占期（从7年而不是5年）和重大税收优惠。1Remdesivir用于抑制病毒复制。 ，是目前正在通过几种药物研究作为covid-19的潜在治疗药物。